Enzalutamide Shows Promise in HR+ Breast Cancer

December 7, 2017
Denise Yardley, MD

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the results from a recent phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive breast cancer.